Found: 4
Select item for more details and to access through your institution.
Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG).
- Published in:
- Breast Cancer Research & Treatment, 2018, v. 172, n. 2, p. 413, doi. 10.1007/s10549-018-4906-8
- By:
- Publication type:
- Article
Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01).
- Published in:
- 2019
- By:
- Publication type:
- journal article
Predicting breast and axillary response after neoadjuvant treatment for breast cancer: The role of histology vs receptor status.
- Published in:
- Breast Journal, 2018, v. 24, n. 6, p. 894, doi. 10.1111/tbj.13085
- By:
- Publication type:
- Article
Chemotherapy and cognitive complaints in women with breast cancer.
- Published in:
- Psycho-Oncology, 2013, v. 22, n. 8, p. 1783, doi. 10.1002/pon.3214
- By:
- Publication type:
- Article